Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services

Contract Services

eFFECTOR partners with Pfizer, Merck to evaluate combination of two immuno-oncology agents eFFECTOR Therapeutics has entered into a clinical collaboration and supply agreement with Pfizer and Merck to evaluate the combination of two immuno-oncology agents in patients with microsatellite stable colorectal cancer (CRC).
Contract Research & Services > Contract Services > News
Immune Pharmaceuticals signs deal to regain global rights for Ceplene Immune Pharmaceuticals has signed an agreement with Mylan company Meda to repurchase assets relating to Ceplene, including the right to commercialize it in Europe and to register and commercialize in several other countries.
Contract Research & Services > Contract Services > News Pfizer to commercialize Basilea's Cresemba drug in Europe Basilea Pharmaceutica International has signed a license agreement with Pfizer for its marketed antifungal Cresemba (isavuconazole) to treat life-threatening invasive mold infections.
Contract Research & Services > Contract Services > News
See more Contract Services news

Latest Contract Services News and Insight

View all Contract Services news or find news targeted to your interests
NSF details how Changing Behaviours can Reduce Risk and Cost
A client investigation identified inconsistencies in hand sanitization, failed retraining efforts and continued problems at an annual cost of over £1.2 million in lost time and unsalable batches. This pharma training case study demonstrates how NSF can help you change GMP behaviours and reduce risk and costs.
Contract Research & Services > Contract Services > Case Studies
NSF asks why Annex 1 is Important to you
| By NSF Health Sciences Pharma Biotech PBR
This white paper details the key reasons for the revision to EudraLex Volume 4, Annex 1: Manufacture of Sterile Medicinal Products. It outlines what you should be asking yourself regardless of the dosage form you are responsible for. It also includes a simple tool to assess the impact on your organization when there is a regulatory change.
Contract Research & Services > Contract Services > White Papers
Heightened FDA Enforcement for Sterility Issuesin Pharma Biotech with NSF
| By NSF Health Sciences Pharma Biotech PBR
NSF analysed all of the warning letters issued to pharma and biologic manufacturers for sterility issues since 2015. This white paper provides detailed insight into our analysis. It includes relative charts and a table with a summary of the regulations cited by the FDA as well as recommendations for closing your compliance gaps.
Contract Research & Services > Contract Services > White Papers
NSF: Essential Rules When Investigating GMP Deviations During Sterile Processing
| By NSF Health Sciences Pharma Biotech PBR
This white paper by John Johnson outlines the key attributes to consider during sterile products manufacturing. It also details five key non-negotiables for investigating pharmaceutical GMP deviations or deficiencies in sterile processing.
Contract Research & Services > Contract Services > White Papers
NSF Explains the Points to Consider when Auditing a Terminally Sterilised Drug Product
| By NSF Health Sciences Pharma Biotech PBR
When conducting an audit of the terminally sterilized pharmaceutical product process, the essential checklist outlined in this white paper by Maxine Fritz will help.
Contract Research & Services > Contract Services > White Papers
Download NSF's New Pharma APP - A Must-Have For Pharmaceutical Professionals
Whether you’re looking to stay up to date with what’s going on in an ever-changing pharmaceutical industry, want an easier and more convenient way to access our latest resources or require help with an immediate business issue, NSF have you covered.
Contract Research & Services > Contract Services > Press Releases
OBI Pharma to acquire Threshold's TH-3424 small-molecule prodrug
Taiwan-based OBI Pharma has agreed to acquire Threshold Pharmaceuticals' TH-3424, a novel small-molecule prodrug that selectively targets cancers overexpressing the enzyme aldo-keto reductase 1c3 (AKR1C3).
Contract Research & Services > Contract Services > News
Vetter and Microdermics Enter into a Strategic Cooperation Agreement
Vetter and Microdermics Enter into a Strategic Cooperation Agreement to Develop Innovative Microneedle Drug Delivery Systems.
Contract Research & Services > Contract Services > Press Releases
Vetter’s Dr. Claudia Roth is appointed to the Fraunhofer Advisory Board
Appointment will allow for active involvement within the Fraunhofer Institute for Manufacturing Engineering and Automation IPA
Contract Research & Services > Contract Services > Press Releases
View all Contract Services news or find news targeted to your interests